MX2018015599A - Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. - Google Patents

Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer.

Info

Publication number
MX2018015599A
MX2018015599A MX2018015599A MX2018015599A MX2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A
Authority
MX
Mexico
Prior art keywords
fusion protein
terminal
enveloped virus
cancer
treatment
Prior art date
Application number
MX2018015599A
Other languages
English (en)
Inventor
Luo Tianci
Molina Rene
CASTILLE Gabriel
Original Assignee
Wellstat Immunotherapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Immunotherapeutics Llc filed Critical Wellstat Immunotherapeutics Llc
Publication of MX2018015599A publication Critical patent/MX2018015599A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se da a conocer una proteína de fusión recombinante. La proteína de fusión comprende: (a) una secuencia de péptidos de CD55, (b) una secuencia conectora C-terminal con respecto a la secuencia de CD55, (c) un dominio transmembrana C-terminal con respecto a la secuencia conectora y (d) un dominio intracelular Cterminal con respecto al dominio transmembrana, la proteína de fusión no contiene un anclaje de GPI. La proteína de fusión puede ser expresada con un péptido de señal secretor N-terminal, el cual es escindido para producir la proteína madura sobre la superficie de una línea de células o un virus envuelto. Un virus oncolítico que expresa la proteína de fusión es resistente a la inactivación del complemento y se puede utilizar para tratar el cáncer.
MX2018015599A 2017-05-10 2018-05-10 Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. MX2018015599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018015599A true MX2018015599A (es) 2019-05-16

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015599A MX2018015599A (es) 2017-05-10 2018-05-10 Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer.

Country Status (12)

Country Link
US (2) US11274141B2 (es)
EP (1) EP3621635A4 (es)
JP (1) JP7161940B2 (es)
KR (2) KR20240073085A (es)
CN (1) CN109414483A (es)
AU (1) AU2018265258B2 (es)
BR (1) BR112018075281A2 (es)
CA (1) CA3026892A1 (es)
IL (1) IL263979B2 (es)
MX (1) MX2018015599A (es)
WO (1) WO2018209052A1 (es)
ZA (1) ZA201808040B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2022182206A1 (ko) * 2021-02-26 2022-09-01 신라젠(주) 항암 바이러스 및 이의 용도
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR20240003051A (ko) * 2022-06-29 2024-01-08 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
WO2024054040A1 (ko) * 2022-09-07 2024-03-14 신라젠(주) 항암 바이러스의 신규 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
DK1486211T3 (da) 1993-04-30 2009-01-19 Wellstat Biologics Corp Sammensætninger til behandling af cancer ved anvendelse af vira
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
EP1030928A1 (en) 1997-11-21 2000-08-30 Gesellschaft für biotechnologische Forschung mbH (GBF) Development of viruses resistant to inactivation by the human complement system
CA2316033A1 (en) 1997-12-22 1999-07-01 The University Of Tennessee Research Corporation Recombinant rhabdovirus containing a heterologous fusion protein
WO1999051625A2 (en) * 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
DE602005023181D1 (de) 2004-07-21 2010-10-07 Dana Farber Cancer Inst Inc Lentivirusvektoren und deren verwendung
JP5050198B2 (ja) * 2006-09-05 2012-10-17 国立大学法人大阪大学 ヒト補体制御因子発現遺伝子およびその利用
EP2118320A4 (en) * 2007-02-06 2010-05-19 Genizon Biosciences Inc GENE CARD OF HUMAN GENES ASSOCIATED WITH HYPERACTIVITY ATTENTION DEFICIT DISORDER (ADHD)
US20100120665A1 (en) * 2007-03-01 2010-05-13 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
EP2702157A1 (en) 2011-04-29 2014-03-05 Keygene N.V. Glyphosate resistance enhancement
BR112013028271B1 (pt) 2011-05-05 2020-11-24 Wellstat Immuno Therapeutics, Llc Polipeptideo, acido nucleico, vetor viral, preparação farmaceutica, bem como uso dos mesmos no tratamento de doenqa mediada por complemento
US9988611B2 (en) * 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
HUE054588T2 (hu) * 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
NZ736022A (en) 2015-04-06 2024-02-23 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
JP2019515019A (ja) 2016-05-19 2019-06-06 ターンストーン リミテッド パートナーシップ 偽型腫瘍溶解性ラブドウイルス及び併用療法におけるそれらの使用

Also Published As

Publication number Publication date
RU2018146446A3 (es) 2021-09-10
CN109414483A (zh) 2019-03-01
EP3621635A4 (en) 2021-02-24
RU2018146446A (ru) 2021-06-10
US20190194292A1 (en) 2019-06-27
EP3621635A1 (en) 2020-03-18
BR112018075281A2 (pt) 2020-02-11
IL263979B2 (en) 2023-09-01
US11274141B2 (en) 2022-03-15
KR20240073085A (ko) 2024-05-24
KR102662049B1 (ko) 2024-05-23
IL263979B1 (en) 2023-05-01
ZA201808040B (en) 2019-09-25
KR20200005721A (ko) 2020-01-16
JP2020519230A (ja) 2020-07-02
AU2018265258B2 (en) 2023-01-05
CA3026892A1 (en) 2018-11-15
AU2018265258A1 (en) 2019-01-17
WO2018209052A1 (en) 2018-11-15
IL263979A (en) 2019-02-28
JP7161940B2 (ja) 2022-10-27
US20220169701A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2018015599A (es) Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer.
PH12017501942A1 (en) Oncolytic adenovirus encoding a b7 protein
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
MX2017008173A (es) Terapias de combinacion con cepas de listeria recombinantes.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12019500750A1 (en) Chimeric antigen receptors for the treatment of cancer
MX2023013883A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos para su uso.
MX2019010812A (es) Proteinas de fusion inmunomoduladoras y sus usos.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
PH12017500042A1 (en) Interleukin-2/interleukin-2-receptor alpha fusion proteins and methods of use
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
PH12016502011A1 (en) Transgene genetic tags and methods of use
AU2016370470A8 (en) Dual controls for therapeutic cell activation or elimination
CY1125797T1 (el) Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου
MX2020005127A (es) Plataforma de presentacion en endosporas basadas en paenibacillus, productos y metodos relacionados.
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
MX2019002903A (es) Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos.
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
EA201491049A1 (ru) Противораковый слитый белок
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
MX2017007303A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
WO2018129200A3 (en) Pac1 receptor agonists (maxcaps) and uses thereof
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.